BaseLaunch announces that Johnson & Johnson Innovation has renewed its commitment becoming latest strategic partner in the second phase

BASEL, Switzerland, Sept. 29, 2020 /PRNewswire/ — BaseLaunch, the Basel Area-based biotech venture accelerator and incubator, today announces their renewed strategic partnership with Cilag GmbH International, one of the pharmaceutical companies of Johnson & Johnson, who becomes the latest company to join the second phase of BaseLaunch’s endeavor to fuel the next generation of biotech companies. The agreement was facilitated by Johnson & Johnson Innovation.

Johnson & Johnson Innovation, which supported BaseLaunch’s first phase, joins recently announced healthcare, pharma, venture fund and biotechnology strategic partners, including Roche, BB Pureos Bioventures, Roivant Sciences, Bridge Biotherapeutics and CSL Behring, in supporting BaseLaunch’s investment in life sciences innovation.

Nerida Scott, Head, Johnson & Johnson Innovation, EMEA, commented: “Incubators and accelerators are central to the global healthcare startup ecosystem. We have been collaborating with BaseLaunch since launch in supporting the growth and development of early-stage biotech ventures and recognize the

Read More